* Kronos Bio Inc KRON.OQ KRON.O is expected to show a
fall in
quarterly revenue when it reports results on May 8 (estimated)
for the period ending March 31 2024
* The San Mateo California-based company is expected to
report a
18.1% decrease in revenue to $1 million from $1.22 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Kronos Bio Inc is for a
loss
of 42 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Kronos Bio
Inc is
$4.13, above its last closing price of $1.02.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.53 -0.52 -0.34 Beat 35.2
Sep. 30 2023 -0.45 -0.51 -0.54 Missed -5.4
Jun. 30 2023 -0.43 -0.46 -0.52 Missed -13
Mar. 31 2023 -0.27 -0.44 -0.46 Missed -3.4
Dec. -0.48 -0.59 -0.56 Beat 4.4
31 2022
Jan. 1 0001 -0.65 -0.65 -0.57 Beat 12.6
Jan. 1 0001 -0.69 -0.69 -0.59 Beat 14.7
Jan. 1 0001 -0.65 -0.66 -0.65 Beat 1.2
This summary was machine generated May 6 at 11:19 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)